Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• BursteinHJPrestrudAASeidenfeldJAmerican Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology201028233784379620625130
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMAromatase inhibitors in breast cancerN Engl J Med2003348242431244212802030
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• BursteinHJTeminSAndersonHAdjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology201432212255226924868023
   PubMed Web of Science ®Google Scholar
• de LaurentiisMArpinoGMassarelliEA meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancerClin Cancer Res200511134741474816000569
   PubMed Web of Science ®Google Scholar
• AmirEMillerNGeddieWProspective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancerJ Clin Oncol201230658759222124102
   PubMed Web of Science ®Google Scholar
• KoboldtDCFultonRSMclellanMDSchmidtMDComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• LiSShenDShaoJEndocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenograftsCell Rep2013461116113024055055
   PubMed Web of Science ®Google Scholar
• Merenbakh-LaminKBen-BaruchNYeheskelAD538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancerCancer Res201373236856686424217577
   PubMed Web of Science ®Google Scholar
• ToyWShenYWonHESR1 ligand-binding domain mutations in hormone-resistant breast cancerNat Genet201345121439144524185512
   PubMed Web of Science ®Google Scholar
• AngusLBeijeNJagerAMartensJWSleijferSESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patientsCancer Treat Rev201752334027886589
   PubMed Web of Science ®Google Scholar
• ForshewTMurtazaMParkinsonCNoninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNASci Transl Med20124136ra68
   Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• HaberDAVelculescuVEBlood-based analyses of cancer: circulating tumor cells and circulating tumor DNACancer Discov20144665066124801577
   PubMed Web of Science ®Google Scholar
• SundaresanTKSequistLVHeymachJVDetection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based AnalysesClin Cancer Res20162251103111026446944
   PubMed Web of Science ®Google Scholar
• GutteryDSPageKHillsANoninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancerClin Chem201561797498225979954
   PubMed Web of Science ®Google Scholar
• JeselsohnRYelenskyRBuchwalterGEmergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerClin Cancer Res20142071757176724398047
   PubMed Web of Science ®Google Scholar
• SchiavonGHrebienSGarcia-MurillasIAnalysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerSci Transl Med20157313313ra182
   PubMed Web of Science ®Google Scholar
• ChandarlapatySChenDHeWPrevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical TrialJAMA Oncol20162101310131527532364
   PubMed Web of Science ®Google Scholar
• ClatotFPerdrixAAugustoLKinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitorOncotarget2016746744487445927801670
   PubMedGoogle Scholar
• FribbensCO’LearyBKilburnLPlasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast CancerJ Clin Oncol201634252961296827269946
   PubMed Web of Science ®Google Scholar
• SpoerkeJMGendreauSWalterKHeterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrantNat Commun201671157927174596
   PubMed Web of Science ®Google Scholar
• WellsGASheaBO’ConnellDThe Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses2011 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed July 23, 2018
   Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• StroupDFBerlinJAMortonSCMeta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) groupJAMA2000283152008201210789670
   PubMed Web of Science ®Google Scholar
• HigginsJPTGreenSCochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]The Cochrane Collaboration2011 Available from: http://handbook-5-1.cochrane.org/Accessed July 23, 2018
   Google Scholar
• YatesLRGerstungMKnappskogSSubclonal diversification of primary breast cancer revealed by multiregion sequencingNat Med201521775175926099045
   PubMed Web of Science ®Google Scholar
• LiJLenferinkAEGDengYErratum: Corrigendum: Identification of high-quality cancer prognostic markers and metastasis network modulesNat Commun201231
   Google Scholar
• ZouJWangEeTumorType, An Algorithm of Discriminating Cancer Types for Circulating Tumor Cells or Cell-free DNAs in BloodGenomics Proteomics Bioinformatics201715213014028389380
   PubMed Web of Science ®Google Scholar
• GaoSTibicheCZouJIdentification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal CancerJAMA Oncol201621374526502222
   PubMed Web of Science ®Google Scholar
• McgeeSRTibicheCTrifiroMWangENetwork Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival OutcomeGen Prot Bioinform2017152121129
   PubMed Web of Science ®Google Scholar
• WangEZamanNMcgeeSMilaneseJSMasoudi-NejadAO’Connor-McCourtMPredictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing dataSemin Cancer Biol20153041224747696
   PubMed Web of Science ®Google Scholar